Send to

Choose Destination
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):319-23. doi: 10.1097/QAI.0000000000000981.

Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection.

Author information

*Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA; †Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Division of Infectious Diseases, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL; §Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles Biomedical Research Institute, Harbor-UCLA, Torrance, CA; ‖Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, OH; and ¶Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD.


To determine the impact of highly active antiretroviral therapy (HAART) on liver disease, we analyzed changes in the aspartate aminotransferase to platelet ratio index (APRI) pre- and post-HAART initiation among 441 HIV-monoinfected and 53 HIV-viral hepatitis-coinfected men. Before HAART, APRI increased 17% and 34% among the HIV-monoinfected and coinfected men, respectively. With HAART initiation, APRI decreased significantly in men who achieved HIV RNA of <500 copies per milliliter: 16% for HIV-monoinfected and 22% for coinfected men. Decreases in APRI were dependent on HIV suppression. This protective effect of HAART decreased after 2 years, particularly in the HIV-monoinfected men.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center